Immunic appoints biopharmaceutical executive Jon Congleton to board [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has announced the appointment of veteran biopharmaceutical executive Jon Congleton to its board of directors, as the company advances its multiple sclerosis program through late-stage development. Congleton brings nearly four decades of experience in the biopharmaceutical industry, with a background spanning drug development, commercialization, and executive leadership, according to Immunic. His work has covered multiple therapeutic areas, including cardiovascular, gastrointestinal, and central nervous system (CNS) conditions. During his career, Congleton was involved in the US launch of Copaxone, a treatment for relapsing forms of multiple sclerosis (MS) developed by Teva Pharmaceuticals Industries. He later led US operations for the product as it became one of the most widely prescribed MS therapies. Congleton currently serves as chief executive officer of Mineralys Therapeutics, where he has overseen the company's transition from a priva
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic (IMUX) was given a new $2.50 price target by Stifel Nicolaus.MarketBeat
- Immunic (IMUX) was downgraded by D. Boral Capital from "buy" to "hold".MarketBeat
- Immunic to Participate in Scientific and Medical Conferences in April [TheStreet.com]TheStreet.com
- Immunic to Participate in Scientific and Medical Conferences in AprilPR Newswire
- Immunic regains compliance with Nasdaq minimum bid price requirement [Seeking Alpha]Seeking Alpha
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Sec Filings
- 4/17/26 - Form SCHEDULE
- 4/14/26 - Form 8-K
- 4/10/26 - Form 8-K
- IMUX's page on the SEC website